Please login to the form below

Not currently logged in
Email:
Password:

Medicines Discovery Catapult appoints CEO

Chris Molloy will take up the lead role in November this year

MDC Chris MolloyThe Alderley Park, Cheshire-based Medicines Discovery Catapult (MDC) has appointed Chris Molloy as its first ever chief executive officer.

Currently chief executive of life sciences recruitment firm The RSA Group, Molloy will take up the lead role at the recently-established MDC in November this year.

As chief executive, he will primarily work with the board of directors and government organisation Innovate UK to develop and implement a new five-year business plan for the drug discovery and early development firm.

Chairman Professor Graham Boulnois, said: “We are delighted to bring Chris on board as we start out exciting journey at the Medicines Discovery Catapult.

“Chris' experience of leading companies operating in life sciences combined with his in-depth knowledge of drug discovery will be of tremendous value to the company.”

Molloy moves to the MDC from The RSA Group, which he joined in 2009 as a non-executive director before becoming chief executive in 2013.

Prior to this, he has served as corporate development and marketing vice-president at IDBS, chief operating officer of Singaporean biotech MerLion Pharmaceuticals, and has held research and development positions at GlaxoKlineSmith.

Molloy said: “I am very much looking forward to building and leading the team at the Medicines Discovery Catapult.

“The Catapult will engage the UK's experienced drug discovery talent and help launch a new generation of drug research and development leaders into a successful future.

“It is an incredibly exciting and forward-thinking organisation that will actively shape the direction of travel in drug discovery and development and enable others in the UK to do so too.”

2nd September 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...